Yati Herbals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 03-07-2024
- Paid Up Capital ₹ 0.10 M
as on 03-07-2024
- Company Age 20 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.60 M
as on 03-07-2024
- Revenue 235.44%
(FY 2022)
- Profit 5265.17%
(FY 2022)
- Ebitda 2019.48%
(FY 2022)
- Net Worth 17.97%
(FY 2022)
- Total Assets 10.74%
(FY 2022)
About Yati Herbals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.60 M.
Ritu Gupta, Mamta Gupta, Nitin Aggarwal, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24239DL2003PTC123718
- Company No.
123718
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Dec 2003
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Yati Herbals?
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Monika Goel  | Director | 26-Dec-2003 | Current |
| Ritu Gupta | Director | 26-Dec-2003 | Current |
| Mamta Gupta | Director | 26-Dec-2003 | Current |
| Nitin Aggarwal | Director | 26-Dec-2003 | Current |
| Santosh Gupta | Director | 26-Dec-2003 | Current |
| Dinesh Goel | Director | 26-Dec-2003 | Current |
Financial Performance and Corporate Structure Insights of Yati Herbals.
Yati Herbals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 235.44% increase. The company also saw a substantial improvement in profitability, with a 5265.17% increase in profit. The company's net worth Soared by an impressive increase of 17.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Yati Herbals?
In 2022, Yati Herbals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sanjivan Anusandhan Private Limited
Active
28 years 4 months Dinesh Goel and Monika Goel are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Syndicate Bank Creation Date: 24 Mar 2007 | ₹0.60 M | Open |
Syndicate Bank Creation Date: 03 Nov 2004 | ₹5.00 M | Open |
How Many Employees Work at Yati Herbals?
Unlock and access historical data on people associated with Yati Herbals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Yati Herbals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Yati Herbals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
